Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	3.71B
Revenue (ttm)	442.59M
Net Income (ttm)	-613.35M
Shares Out	90.57M
EPS (ttm)	-7.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	763,912
Open	40.98
Previous Close	41.12
Day's Range	39.85 - 41.08
52-Week Range	31.52 - 54.56
Beta	0.60
Analysts	Strong Buy
Price Target	86.80 (+111.91%)
Earnings Date	Aug 1, 2024

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and ad...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,276
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE

Financial Performance

In 2023, RARE's revenue was $434.25 million, an increase of 19.52% compared to the previous year's $363.33 million. Losses were -$606.64 million, -14.25% less than in 2022.

Analyst Forecast

According to 15 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price forecast is $86.8, which is an increase of 111.91% from the latest price.

Price Target

$86.8

(111.91% upside)

Analyst Consensus: Strong Buy